生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

交易中 07-13 10:20:56 EDT

1,222.59

-21.61

-1.74%

最高1,244.19	最低1,221.59	成交量2.42亿
今开1,244.19	昨收1,244.20	日振幅1.82%
总市值0.00	流通市值0.00	总股本0.00
成交额33.44亿	换手率--	流通股本0.00
市净率7.767958	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1222.5868,"timestamp":1783952456419,"preClose":1244.1975,"halted":0,"volume":242120802,"delay":0,"changeRate":-0.017369,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-21.610718,"latestTime":"07-13 10:20:56 EDT","open":1244.1936,"high":1244.1936,"low":1221.5936,"amount":3344467365.065355,"amplitude":0.018164,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1783972800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.767958,"peRate":-170.403179,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"1198173192","title":"艾吉纳斯公司宣布超额认购至多3.4亿美元私募，以推进BOT+Bal新辅助治疗MSS结肠癌的注册性Robbin试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1198173192","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198173192?lang=zh_cn&edition=full","pubTime":"2026-07-13 18:01","pubTimestamp":1783936884,"startTime":"0","endTime":"0","summary":"艾吉纳斯公司宣布，其一项至多3.4亿美元的私募融资获得超额认购。此次融资旨在推进其BOT+Bal联合疗法作为新辅助治疗，用于微卫星稳定型结肠癌患者的注册性Robbin临床试验。\n该笔资金将直接用于支持关键性试验的开展，标志着公司核心管线向前迈出了重要一步。市场对此次融资反应积极，显示出投资者对该疗法潜力的信心。此举有望加速该创新疗法的发展进程，为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGEN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176205308","title":"RBC将Kymera Therapeutics评级下调至行业表现，目标价上调至115美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176205308","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176205308?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:33","pubTimestamp":1783935195,"startTime":"0","endTime":"0","summary":"RBC资本市场调整了对Kymera Therapeutics Inc.的投资评级，将其从“跑赢大盘”下调至“行业表现”。与此同时，该机构将其目标股价从106美元上调至115美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651194918","title":"美股盘前中概股涨跌互现，理想汽车、百济神州涨3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651194918","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651194918?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:04","pubTimestamp":1783929885,"startTime":"0","endTime":"0","summary":"7月13日，美股盘前中概股涨跌互现，理想汽车、百济神州涨3%，京东、网易涨2%，阿里巴巴涨0.6%，哔哩哔哩、拼多多、百度跌1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607133803774313.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607133803774313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4509","LU0359201612.USD","HK0000306685.HKD","LU1046422090.SGD","LU1769817096.USD","LU0738911758.USD","LU2177674079.SGD","IE00BFMHRM44.USD","LU1720050803.USD","LU0633140727.USD","LU2279858448.HKD","IE00BVYPNQ40.USD","LU0348816934.USD","LU1868837565.USD","BABO","LU0310800965.SGD","LU0605514214.HKD","LU0048580855.USD","BK4527","LU1868837722.USD","SG9999002463.SGD","LU0235996351.USD","LU1115378108.SGD","CLIX","LU0661504455.SGD","BK4553","LU0370786039.SGD","LU1043141123.HKD","IE00BVYPNP33.GBP","LU1303224171.USD","LU0823413587.USD","BK4077","LU1152091754.HKD","LU0417516902.SGD","LU1981816686.USD","LU1960683339.HKD","LU0326950275.SGD","LU0456842615.SGD","688235","LU0463099449.HKD","BK4554","LU0348827113.USD","EVS.SI","LU1023057109.AUD","LU0516422440.USD","LU0328353924.USD","LU0918141887.USD","LU1794554557.SGD","LU1868838027.USD","LU0545039389.USD","BK4563","BK4607","LU0561508036.HKD","LU1719994722.HKD","BK4526","LU0797268264.HKD","KWEB","LU2257852520.SGD","09999","LU0594300179.USD","LU0259732245.USD","LU0359202008.SGD","LU0128525689.USD","BK4504","IE00BGV7N243.SGD","ONC","LU0173614495.USD","LU0052756011.USD","LU0588546209.SGD","LU0516423174.USD","LU1988902786.USD","LU0640798160.USD","LU1823568750.SGD","LU1282648689.USD","LU1993786604.SGD","LU1003077747.HKD","LU0650527681.SGD","BK4555","BK4581","LI","LU0047713382.USD","LU0348825331.USD","LU0210526637.USD","BK4588","LU0359201885.HKD","IE00BGHQDM52.EUR","BK4531","LU0502904849.HKD","JD","BK4551","BK4614","LU0823038988.USD","LU1121112475.USD","LU2039709279.SGD","LU1105468828.SGD","LU1267930227.SGD","IE00B0JY6N72.USD","BK4543","BK4513","LU0979878070.USD","LU0455707207.USD","HK0000320223.HKD","LU1171460220.USD","LU1770034418.SGD","IE0034224299.USD","LU0651946864.USD","BABU","LU1880383366.USD","LU0531971595.HKD","BILI","LU1046421795.USD","ALBmain","LU1043141396.HKD","BK4532","LU0501845795.SGD","BK4099","BK4565","LU0327786744.USD","LU1688375341.USD","LU2008162690.USD","LU0633140560.USD","BK4085","LU0516422366.SGD","LU0823397103.USD","BK4548","BK4585","LU0348805143.USD","LU0594300419.USD","LU0823413660.USD","DRAG","LU2399975544.HKD","BK4612","HK0000320264.USD","LU0823397285.USD","BK4577","ONLN","LU0329678337.USD","LU0918141705.HKD","LU1323998911.USD","LU0949170772.SGD","PDD","BK4566","LU1242518857.USD","ESPO","LU1242518931.SGD","09626","LU0516423091.SGD","LU1051769294.HKD","BK4538","06160","LU0589944569.HKD","LU0251143458.SGD","SG9999014674.SGD","LU1961090484.USD","LU0329678170.USD","LU0231483743.USD","BK4558","BK4514","BABW","BK4602","BIDU","LU0516422952.EUR","LU0708995583.HKD","LU0072913022.USD","BABA","IE00B29SXG58.USD","HK0000306701.USD","LU0572944931.SGD","09618","LU0878005551.USD","LU2148611432.USD","LU0348788117.USD","LU0651947912.USD","LU1008478684.HKD","LU1251922891.USD","BK4503","LU0039217434.USD","LU0117841782.USD","BIDG","LU0143863198.USD","BK4587","LU0315179316.USD","LU0871576103.HKD","LU1808992512.USD","LU2242644610.SGD","IE00B3M56506.USD","BK4574","LU0426417589.USD","BABX","LU0880133367.SGD","IE00BMCWC346.EUR","LU0823039010.USD","NTES","BK4533","KBAB","LU0821914370.USD","LU0823426308.USD","LU1515016050.SGD","BK4139","LU0072462343.USD","BK4579","FDNI","BK4122","LU1048588211.SGD","LU0737861772.HKD","LU0244354667.USD","IE00BF5LJ272.USD","LU1956131251.USD","NERD","BK4220","BK4502","KBDU","LU0683595622.HKD","BK4501","LU0307460666.USD","LU0106959298.USD","LU1152091168.USD","LU1235295612.USD","LU2226246903.HKD","HERO","LU1188198961.HKD","SG9999002562.SGD","BK4534","BK4552","09988","LU0067412154.USD","LU0164865239.USD","LU0140636845.USD","BK4535","LU1235294995.USD","LU0143863784.USD","LU2211817866.USD","LU0052750758.USD","KPDD","BBYY","LU0049112450.USD","LU0456846285.SGD","ODDS","LU1769817179.HKD","SG9999002828.SGD","LU0553294199.USD","IE00BYV24P56.USD","LU0426412945.USD","LU1228905540.USD","LU1228905037.USD","LU0456827905.SGD","LU0287142896.SGD","BK4510","LU2264538146.SGD","KJD","BK4575","LU0545562505.USD","LU1064131342.USD","02015","LU1048596156.SGD","LU1051768304.USD","BK4524","LU2087589342.USD","LU0994945656.USD","LU0320764599.SGD","LU0823426480.USD","IE0008368742.USD","09888","BK4505","LU0051755006.USD","LU1880383440.USD","PDDL","LU0348814723.USD","IE0031814852.USD","HK0000165453.HKD","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122535319","title":"因塞特医疗公布Latarcibart一期/二期数据，显示对血管性血友病患者显著减少出血","url":"https://stock-news.laohu8.com/highlight/detail?id=1122535319","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122535319?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:03","pubTimestamp":1783929781,"startTime":"0","endTime":"0","summary":"因塞特医疗近日公布了其候选药物Latarcibart的一期/二期临床试验数据。数据显示，该药物在治疗血管性血友病（VWD）患者方面展现出令人鼓舞的疗效，能够显著减少患者的出血事件。\n此次公布的数据突显了Latarcibart在控制这类出血性疾病方面的潜力。试验结果表明，接受治疗的患者出血频率大幅降低，这为改善患者的生活质量带来了新的希望。该药物的作用机制旨在针对疾病根源，提供一种新的治疗选择。\n目前，针对血管性血友病的有效治疗方案仍然有限。Latarcibart的积极数据若能在后续更大规模的临床试验中得到验证，将有望填补这一领域的医疗需求。公司将继续推进该药物的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","IDNA","BK4550","BK4532","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651160208","title":"杰富瑞：将Moderna(MRNA.US)目标价从53美元上调至60美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2651160208","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651160208?lang=zh_cn&edition=full","pubTime":"2026-07-13 11:55","pubTimestamp":1783914940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4568","LGHT","BK4533","UUP","MRNX","BK4532","GNOM","MRNA","IDNA","BK4139","BK4585","WDNA","BK4501","BK4534","BK4548","BK4551","MRNY","BK4588","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650150488","title":"亚洲规模最大ACGN展会！BilibiliWorld三天吸引40万人次参展","url":"https://stock-news.laohu8.com/highlight/detail?id=2650150488","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650150488?lang=zh_cn&edition=full","pubTime":"2026-07-12 14:28","pubTimestamp":1783837680,"startTime":"0","endTime":"0","summary":"新浪科技讯 7月12日下午消息，哔哩哔哩 举办的综合性ACGN展会BilibiliWorld 2026落下帷幕。数据显示，三天时间，BW2026共吸引来自全球30多个国家及地区的40万人次参展，覆盖国家及地区数量较2025年进一步增加。今年全球共170家展商参与，现场展出近千台痛车，超6万名Coser到场参与互动。　　据介绍，BW2026延续了去年的展会规模与展出面积，覆盖上海国家会展中心8个展馆，共计展出面积24万平方米，是亚洲规模最大的ACGN综合性展会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tech/internet/2026-07-12/doc-inihppvw5898407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ACGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650760159","title":"福泰制药百亿美元并购透露了什么讯号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2650760159","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650760159?lang=zh_cn&edition=full","pubTime":"2026-07-11 22:55","pubTimestamp":1783781749,"startTime":"0","endTime":"0","summary":"01百亿美元级现金并购的底气福泰制药2025年全年营收120.01亿美元，同比增长9%，非GAAP净利润47.5亿美元，毛利率维持85%以上高位，账面现金及有价证券超过123亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1783569458583958068","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU2417539215.USD","VRTX","LU1778281490.HKD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU2236285917.USD","LU0079474960.USD","LU1093756168.USD","BK4567","SG9999001176.USD","LU1585245621.USD","BIB","IE00B894F039.SGD","KCE","SGXZ57979304.SGD","BK4532","MYLD","XMMO","IDNA","IE0009355771.USD","BK4139","LU1069344957.HKD","LU0320765992.SGD","LU2462157665.USD","BK4588","LU0823416689.USD","SG9999001176.SGD","LU0289739699.SGD","LU0234570918.USD","IE00B4R5TH58.HKD","PBE","LU0109394709.USD","LU2324357040.USD","CALF","IE00B19Z3581.USD","LU0058720904.USD","BBH","IE0002270589.USD","IE00BFTCPJ56.SGD","LU1035775433.USD","IE00BJJMRZ35.SGD","IBBQ","IE00B19Z9P08.USD","IE00BZ9MQY76.HKD","LU0061475181.USD","LU1093756325.SGD","LU2362540622.SGD","IE0002141913.USD","IBB","IE00B19Z9Z06.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133823051","title":"ETF日报｜2倍做多Cerebras Systems ETF涨近17%；2倍做多Meta ETF涨12%；材料与地产带动行业走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1133823051","media":"ETF追踪","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133823051?lang=zh_cn&edition=full","pubTime":"2026-07-11 06:02","pubTimestamp":1783720938,"startTime":"0","endTime":"0","summary":"美股ETF涨幅Top5$2倍做多CBRS ETF-Leverage Shares$上涨16.78%。该产品两倍做多AI芯片公司$Cerebras Systems$，因底层公司股价上涨，杠杆机制放大当日涨幅。该产品两倍做多Cerebras Systems，随标的走高，同步体现杠杆放大效应。$Corgi U.S. Regional Banks 2x Daily ETF$上涨12.03%。$Corgi META 2x Daily ETF$上涨12.00%。$AOT Software Platform ETF$上涨11.96%。美股ETF跌幅Top5$Defiance Daily Target 2X Long MRNA ETF$下跌21.77%。$Leverage Shares 2X Long OPEN Daily ETF$下跌20.38%。$罗素2000指数三倍做空ETF$上涨1.53%。$香港ETF-iShares MSCI$上涨1.37%。$核能指数ETF-Market Vectors$上涨1.23%。债券ETF涨幅Top 5$First Trust Emerging Markets L","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFFR","LU1145028129.USD","DUST","LU1839511570.USD","OPEN","IE00BJJMRY28.SGD","SAA","BK4606","JDST","IGLD","LU0353189680.USD","IE00BMPRXN33.USD","LU1791710400.SGD","LU1803068979.SGD","IE00BKDWB100.SGD","LU1116320737.USD","GDXJ","LU1718418525.SGD","LU0256863811.USD","SG9999002232.USD","LU0203345920.USD","LU1059921491.USD","XLB","SG9999014880.SGD","LU2764262908.HKD","IE0034235303.USD","BK4551","BK4532","LGHT","BK4587","LU1201861249.SGD","KGLD","LU2168564149.EUR","IE00B19Z3B42.SGD","LU2250418816.HKD","LU0170899867.USD","IE00BGHQF417.EUR","LU2420271590.USD","UMAL","LU0823434740.USD","LU1791710582.SGD","LU0823414551.USD","LU1267930490.SGD","LU2247934214.USD","SHNY","LU2456880835.USD","SG9999002224.SGD","LU0552385451.USD","LU0106261372.USD","LU0109392836.USD","GDXU","LU2294711713.HKD","VELO","LU2054465674.USD","IE00BMPRXR70.SGD","MADE","LU0323591593.USD","IE00BKVL7J92.USD","LU1153585028.USD","VOO","IE00B775H168.HKD","LU0276348264.USD","LU0784385840.USD","NVOH","SGXZ81514606.USD","IE0003U64NQ7.SGD","MRNY","XDAT","BK4501","DGP","LU0476273544.USD","LU0661504455.SGD","LU2505996509.AUD","LU2473716301.USD","LU2065169927.USD","RING","IE000KEQY171.SGD","LU1564329461.SGD","NLR","LU0949170426.SGD","LU1732799900.SGD","LU1551013342.USD","META","LU0912757837.SGD","IE00BD6J9T35.USD","LU0162691827.USD","LU2487616109.SGD","BK4077","GB00B4LPDJ14.GBP","LU2087621335.USD","PSCM","IE00BQXX3C00.GBP","LU1670710661.SGD","BK4568","NUGT","OPEX","LU2322448957.HKD","IE00B19Z8X17.USD","LU0211327993.USD","VOX","LU2272731782.SGD","BK4548","LU0056508442.USD","LU1670711123.USD","SG9999017495.SGD","IE0004445015.USD","SG9999014898.SGD","LU0823421416.USD","LU0889565833.HKD","LU2357305700.SGD","LU0708995401.HKD","LU2168564495.EUR","IE00B1XK9C88.USD","IWM","LU1778281490.HKD","BK4207","LU1670711040.USD","USG","LU1366192091.USD","IE00B19Z3581.USD","LU1564329628.SGD","SPYQ","LU0820561909.HKD","LU2462591350.SGD","UWM","LU0208291251.USD","LU2242650005.HKD","BK4592","LU2023250330.USD","LU0979878070.USD","FAAR","LU2746668461.USD","LU0203202063.USD","LU0210528500.USD","BK4535","IAU","WDNA","LU2403377893.USD","LU0957791311.USD","LU2552382215.SGD","SG9999004303.SGD","LU0174119429.USD","LU1861559042.SGD","EBND","LU2552382132.HKD","IE00BZ1G4Q59.USD","IE00BFSS7M15.SGD","LU0683600562.USD","LU0795875169.SGD","LU1069344957.HKD","SGDJ","METW","SGXZ31699556.SGD","LU0640476718.USD","SPUU","MRNX","POWR","LU1868836914.USD","GB00B4QBRK32.GBP","LU1066051498.USD","LU0068578508.USD","DMAX","HK0000304805.HKD","LU0354030511.USD","FGDL","LU1992135399.USD","LU1917777945.USD","LU2552382058.USD","YGLD","LU0256863902.USD","RSPC","VELL","LU0433182093.SGD","IDNA","IE00B3SWFQ91.USD","LU2065171311.SGD","ZAP","LTL","SGXZ99366536.SGD","LU2264538146.SGD","SG9999015952.SGD","LU2756315318.SGD","LU2543165471.USD","LU1548497426.USD","LU2168564222.USD","LU0823414478.USD","UMDD","LU1551013425.SGD","LU2237957811.SGD","SPYM","LU1814569148.SGD","UGL","LU2505996681.GBP","LU0314104364.USD","SG9999015945.SGD","MRNA","IE00BQXX3F31.USD","LU2063271972.USD","LU1670710588.SGD","IE00BJTD4V19.USD","LU2237957902.USD","TWM","NULC","LU0444973449.USD","RWM","BK4585","BK4504","DIG","LU1261432733.SGD","LU0980610538.SGD","LU2213496289.HKD","LU0823434583.USD","LU2417539215.USD","LU0215105999.USD","LU2360032135.SGD","XKRE","BK4079","IE00B3CCJ633.GBP","LU1232071149.USD","UPRO","LU1564329032.USD","LU1720051108.HKD","LU2087625088.SGD","LU1988902786.USD","LU0154236417.USD","IE00BJTD4N35.SGD","LU0878866978.SGD","LU0072461881.USD","LU2360106780.USD","LU2463028550.USD","IE00B19Z9505.USD","LU2404859667.USD","IE00BFSS8Q28.SGD","LU0082616367.USD","IE00B2PGVK34.USD","LU2106854487.HKD","LU0234570918.USD","BGLD","LU0061474960.USD","LU1571399168.USD","LU2720916845.USD","LU2249611893.SGD","LU1116320901.HKD","IE000ITXATA3.USD","LU2023250843.SGD","NANR","LU1629891620.HKD","IVV","ELD","FEMB","SMAX","LU1127390331.HKD","EBND.AU","LU2461242641.AUD","TNA","IE00BQXX3D17.EUR","LU1496350502.SGD","LU2357125470.USD","LU0466842654.USD","LU2317271919.USD","LU0203201768.USD","FCOM","LU2746668974.SGD","LU2360107325.USD","SH","SPYU","LU0788109477.HKD","LU1035775433.USD","LU1868837300.USD","SPXU","URTY","GDXD","FBYY","IE0001KFT4U8.USD","LU0070302665.USD","LU0096362180.USD","LU0265550946.USD","LU0149725797.USD","SGOL","BK4603","LU1697837992.HKD","XLC","LU0210536198.USD","IE0034235188.USD","SG9999001077.SGD","IE00B5949003.HKD","GLL","LU0820562030.AUD","XME","SPY","SOCL","IE00BWXC8680.SGD","BK4141","LU0133085943.USD","SG9999015978.USD","LU0648001328.SGD","LU0672654240.SGD","LU1366333091.USD","LU2326559502.SGD","LU1242518931.SGD","BK4507","IE0009356076.USD","MMAX","BK4588","LU2430703251.USD","LU2272731600.USD","GLD","LU0316494557.USD","METD","SG9999014914.USD","GLDM","CBRS","LU0553294199.USD","LU1861219969.SGD","LU2133065610.SGD","YSPY","LU1084165304.USD","IE0004445239.USD","DRN","JNUG","DXJ","EWZ","LU2506951792.HKD","AAAU","GLDY","GOAU","LU0061475181.USD","LU0080751232.USD","LU2361045086.USD","SPXL","LU2756315664.SGD","HK0000304797.USD","METU","LU1003077747.HKD","DGZ","IE00BN29S564.USD","BK4561","XRT","LU0820561818.USD","LU0198837287.USD","518880","AOTS","LU1642822529.SGD","IAUI","LU0949170772.SGD","LU1852331112.SGD","LU0320765489.SGD","LU0726765562.USD","LU0784383803.USD","SG9999015986.USD","LU2168564065.EUR","SG9999018865.SGD","HIBL","LU0528227936.USD","LU1119994496.HKD","GDXY","LU2322448791.USD","LU2265009873.SGD","LU2430703095.HKD","LU0964807845.USD","LU1429558221.USD","OPEG","UYM","LU0985489474.SGD","SG9999018857.SGD","LEMB","LU0072462426.USD","LU0957808578.USD","LU1815336760.USD","LU0053666078.USD","GRID","GB00BDT5M118.USD","IAUM","LU1674673428.USD","LU1732800096.USD","LU1564329115.USD","LU2381873111.SGD","SPYH","LU1699723380.USD","CEF","CBRX","LU2458330169.SGD","OIH","IE00BMPRXQ63.HKD","METV","EWH","LU0985320562.USD","LU1804176565.USD","LU0786609619.USD","LU0690374615.EUR","LU0943347566.SGD","LU1064131342.USD","LU0784384876.USD","LU2361044949.HKD","LU0348723411.USD","LU0724617625.USD","LU0096364046.USD","LU1316542783.SGD","UMAC","DULL","LU1670627923.USD","LU1868836757.USD","IE000W1ABFV2.USD","LU0738911758.USD","LU0417517546.SGD","DBC","SG9999014906.USD","SGXZ51526630.SGD","LU1989764748.USD","SSO","SDS","TZA","LU0787776722.HKD","GLTR","LU0061474705.USD","LU0308772762.SGD","LU1815333072.USD","LU1974910355.USD","LU2764263203.CNY","LU0225283273.USD","LU0882574139.USD","LU0642271901.SGD","HK0000914686.HKD","LU1242518857.USD","LU2462157665.USD","LU2125154935.USD","GDX","LU0719512351.SGD","IE0002270589.USD","LU2764263039.SGD","FDN","HK0000914660.USD","LU1280957306.USD","IE00B1BXHZ80.USD","EMTL","BK4533","LU1670628061.USD","LU2236285917.USD","IE00B4YYXB79.USD","159831","MVV","SGXZ23171101.USD","IE00BK4W5L77.USD","BK4534","OUNZ","IE00BJJMRX11.SGD","LU1868836591.USD","LU1868837136.USD","LU0157215616.USD","LU0011850046.USD","BK4524","IE00B7KXQ091.USD","LU2430703178.SGD","LU1992135472.HKD","LU2347655073.USD","LU2592432038.USD","DZZ","LU0690374961.EUR","LU0265550359.USD","LU0795875086.SGD","LU1823568750.SGD","LU0444971666.USD","LU2347655156.SGD","LU1861558580.USD","IE00B19Z8W00.USD","FBL","IE0009G5SDU7.USD","LU0070217475.USD","LU2458330243.SGD","LU1046421795.USD","BK4157","FBY","LU0345769631.USD","LU1674673691.USD","LU2065170008.USD","LU2272731865.HKD","SPDN","EMLC","LU0210533765.USD","LU0006306889.USD","LU0203347892.USD","LU2023250504.SGD","LU2168563687.JPY","LU0127658192.USD","PHYS","LU0109391861.USD","LU1489326972.SGD","LU0689472784.USD","LU0310799852.SGD","FBX","LU1235294995.USD","BK4550","LU1435385759.SGD","BK7142","OGIG","LU0077335932.USD","LU0784385170.HKD","LU1267930730.SGD","PICK","BK4096","NVOX","LU2404859741.USD","LU2097829019.USD","LU0097036916.USD","LU0130102774.USD","GBUG","IE00B4JS1V06.HKD","PALL","LU2065171402.SGD","LU1989764664.SGD","CBRG","LU2602419157.SGD","BEGS","SPXS","BK4562","LU1720051017.SGD","LU0234572021.USD","GOLY","GNOM","LU0353189763.USD","LU2361044865.SGD","MIDU","IE00BK4W5M84.HKD","LU0545039389.USD","BK4543","LU0211328371.USD","ETN","IE00BJLML261.HKD","159934","IE00B7SZLL34.SGD","LU0320765059.SGD","BK4139","LU1301847155.USD","LU2860962120.EUR","LU0354030438.USD","EMBD","LU1074936037.SGD","BAR","LU2125154778.USD","LU0079474960.USD","SGDM","IE000YTNTUN2.SGD","LU1066053197.SGD","IE00BZ199S13.USD","LU0345769128.USD","IE0005OL40V9.USD","LU1914381329.SGD","LU1861214812.USD","LU0211331839.USD","BTGD","DBP","LU0267386448.USD","VTWO","LU2896262040.SGD","LU0823421333.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107741368","title":"Veraxa Biotech任命Carl Von Halem为临时首席财务官，接替Torsten Bürgermeister","url":"https://stock-news.laohu8.com/highlight/detail?id=1107741368","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107741368?lang=zh_cn&edition=full","pubTime":"2026-07-11 04:06","pubTimestamp":1783713985,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG已任命Carl Von Halem担任临时首席财务官，他将接替即将离任的Torsten Bürgermeister。此项人事变动即刻生效，标志着公司财务管理层进入新的过渡阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140024184","title":"Q32 Bio将于2026年7月13日公布Bempikibart治疗斑秃的Signal-aa临床试验B部分36周主要结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1140024184","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140024184?lang=zh_cn&edition=full","pubTime":"2026-07-11 04:06","pubTimestamp":1783713980,"startTime":"0","endTime":"0","summary":"Q32 Bio公司宣布，将于2026年7月13日公布其候选药物Bempikibart用于治疗斑秃的Signal-aa临床试验B部分的36周主要结果。此次数据披露备受市场关注，其结果将对该药物的后续开发路径及公司的估值前景产生重要影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650132294","title":"Moderna(MRNA.O)收跌11%，创下自2025年5月以来最大跌幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2650132294","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650132294?lang=zh_cn&edition=full","pubTime":"2026-07-11 04:03","pubTimestamp":1783713806,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MRNY","LGHT","MRNX","BK4548","BK4585","BK4501","BK4532","WDNA","BK4533","IDNA","BK4139","BK4551","BK4568","GNOM","MRNA","BK4534","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650634136","title":"纳斯达克生物科技指数一度跌超3%，成分股Kyverna Therapeutics目前跌12.45%，Prime Medi","url":"https://stock-news.laohu8.com/highlight/detail?id=2650634136","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650634136?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:49","pubTimestamp":1783694978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NBI","KYTX","BK4139","BK4583","SIGA","BK4007","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153285521","title":"格陵兰矿业生物技术部门获澳大利亚专利授权 克洛托基因疗法技术瞄准神经肌肉疾病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1153285521","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153285521?lang=zh_cn&edition=full","pubTime":"2026-07-10 20:02","pubTimestamp":1783684939,"startTime":"0","endTime":"0","summary":"格陵兰矿业（Greenland Mines）旗下生物技术部门宣布，其针对神经肌肉疾病的克洛托（Klotho）基因疗法技术已获得澳大利亚专利授权。这一进展标志着该公司的创新治疗技术在知识产权保护与国际认可方面取得重要突破，为后续的研发与商业化进程奠定了坚实基础。克洛托基因疗法旨在通过靶向特定的基因机制，为罹患神经肌肉疾病的患者提供潜在的新型治疗方案。专利的授予不仅增强了该技术的法律保护屏障，也提升了其在全球生物医药领域的竞争地位。公司表示，将继续推进相关技术的临床前与临床研究，以期早日将创新疗法惠及患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRML","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157352361","title":"FibroBiologics提交SEC文件：注册出售股东至多1253万股普通股转售","url":"https://stock-news.laohu8.com/highlight/detail?id=1157352361","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157352361?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:07","pubTimestamp":1783678031,"startTime":"0","endTime":"0","summary":"FibroBiologics已向美国证券交易委员会提交文件，为其部分出售股东注册了高达1253万股普通股的转售资格。此举意味着，持有这些已注册股份的股东未来可在公开市场出售这些股票，而公司本身不会从此次转售中获得任何收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165174574","title":"标普道琼斯指数宣布：Solaris Energy Infrastructure, Inc.将取代Catalyst Pharmaceuticals，纳入标普小盘600指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1165174574","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165174574?lang=zh_cn&edition=full","pubTime":"2026-07-10 05:18","pubTimestamp":1783631895,"startTime":"0","endTime":"0","summary":"标普道琼斯指数公司宣布，将对标普小盘600指数（S&P SmallCap 600）的成分股进行调整。根据其声明，Solaris Energy Infrastructure, Inc.将取代Catalyst Pharmaceuticals在该指数中的位置。\n此次调整旨在确保指数能够持续反映美国小盘股市场的代表性表现。Solaris Energy Infrastructure, Inc.的加入与Catalyst Pharmaceuticals的剔除，预计将在指数下一次定期调整时生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4139","BK4179","IE00B19Z6F94.USD","IE00B66KJ199.SGD","XES","IE0034390439.USD","IE0031619046.USD","CPRX","SEI","OIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102164326","title":"伊芙美尔医疗公布初步销售业绩：2026年第二季度产品销售额增长12%，上半年累计增长21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102164326","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102164326?lang=zh_cn&edition=full","pubTime":"2026-07-10 04:06","pubTimestamp":1783627584,"startTime":"0","endTime":"0","summary":"根据未经审计的初步销售数据，伊芙美尔医疗在2026年第二季度实现了产品销售额12%的同比增长。同时，该公司在2026年上半年的累计产品销售额较去年同期增长了21%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176798581","title":"Serina Therapeutics宣布Ser-252用于晚期帕金森病的1B期注册试验队列1哨点给药完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1176798581","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176798581?lang=zh_cn&edition=full","pubTime":"2026-07-10 00:13","pubTimestamp":1783613597,"startTime":"0","endTime":"0","summary":"Serina Therapeutics宣布，其用于治疗晚期帕金森病的候选药物Ser-252，其1B期注册试验第一队列的哨点给药阶段现已顺利完成。这一进展标志着该药物临床开发过程中的一个重要节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167833053","title":"阿尔尼拉姆制药公司股价大涨15.5%，因阿斯利康神经疾病药物Wainua心脏病后期试验失败","url":"https://stock-news.laohu8.com/highlight/detail?id=1167833053","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167833053?lang=zh_cn&edition=full","pubTime":"2026-07-09 21:35","pubTimestamp":1783604157,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司股价飙升超过15%，这一显著涨幅源于其竞争对手阿斯利康的一款药物在关键临床试验中遭遇挫折。阿斯利康与合作伙伴Ionis Pharmaceuticals开发的神经疾病治疗药物Wainua，在一项针对特定心脏病患者的后期研究中未能达到主要目标。\n市场对此反应迅速，投资者将目光投向了阿尔尼拉姆。该公司拥有针对相似适应症的在研药物，此次竞争对手的试验失利，被广泛视为为阿尔尼拉姆的产品扫清了潜在的竞争障碍，或至少推迟了其面临的直接市场挑战。这一事件凸显了生物制药领域激烈的竞争动态，单一临床结果足以引发相关公司市场估值的剧烈波动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","LU0882574055.USD","LU0114720955.EUR","PBE","BK4585","BK4588","BK4139","ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650924739","title":"Cardiol Therapeutics将出席B. Riley Mind, Muscle & Vision峰会炉边谈话","url":"https://stock-news.laohu8.com/highlight/detail?id=2650924739","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650924739?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:54","pubTimestamp":1783601672,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc．宣布，将参加于2026年7月16日在波士顿举行的B． Riley Securities Mind， Muscle & Vision Summit，并在当日下午12：20进行炉边谈话。　　此次峰会为B． Riley Securities主办的单一医疗健康会议，聚焦神经学、肌肉及眼科疾病领域的创新成果。　　Cardiol Therapeutics是一家处于后期阶段的生命科学公司，专注于推进心脏疾病抗炎和抗纤维化疗法的开发。　　Cardiol目前正在推进MAVERIC项目，评估CardiolRx治疗复发性心包炎的疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-09/doc-inihfihx8573744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169751450","title":"Fate Therapeutics获FDA批准其FT839候选产品新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1169751450","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169751450?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:32","pubTimestamp":1783600338,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc宣布，其候选产品FT839的新药临床试验申请已获得美国食品药品监督管理局的批准。这一进展标志着该产品向临床开发阶段迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}